Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET

Company Participants

Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO
Alfred Sandrock - President and Chief Executive Officer
Toby Ferguson - Chief Medical Officer
Todd Carter - Chief Scientific Officer
Nathan Jorgensen - Chief Financial Officer

Conference Call Participants

Phil Nadeau - TD Cowen
Jack Allen - Robert W. Baird
Joon Lee - Truist Securities
Jay Olson - Oppenheimer & Co.
Lili Nsongo - Leerink Partners
Patrick Trucchio - HC Wainwright

Operator

Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please note that today's call is being recorded. A replay of today's call will be available on the Investors section of the company website approximately two hours after completion of this call.

I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer at Voyager.

Trista Morrison

Thank you. And good afternoon. We issued our third quarter 2024 financial results press release this afternoon. The press release and 10-Q are available on our website.

Joining me on today's call are Dr. Al Sandrock, our Chief Executive Officer; Dr. Toby Ferguson, our Chief Medical Officer; and Dr. Todd Carter, our Chief Scientific Officer. We will also be joined for the Q&A portion of the call by Dr. Nathan Jorgensen, our Chief Financial Officer.

Before we get started, I'd like to remind everyone that during this call, Voyager representatives may make forward-looking statements as noted in slide 2 of today's deck. These statements are based on our current expectations and beliefs. They are subject to risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings, which are available on our website for additional detail.

And now, I will turn the call over to Al.

Alfred Sandrock

Good afternoon, everyone, and thank you for joining us. Please turn to slide 3. At Voyager, we are leveraging the power of human genetics to discover and deliver transformative medicines that address the root cause of neurological diseases.

Our four pillars of value include, first, our pipeline of four wholly-owned and and 14 partnered programs. During the third quarter, we completed enrollment and dosing in the single ascending dose trial of VY7523, our anti-tau antibody for Alzheimer's disease. We also recently saw encouraging third party clinical data with another anti-tau antibody for Alzheimer's disease, which Toby will talk about shortly.